Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Preferred Stock Liabilities: 2023-2025

Historic Preferred Stock Liabilities for Lifecore Biomedical (LFCR) over the last 2 years, with May 2025 value amounting to $46.1 million.

  • Lifecore Biomedical's Preferred Stock Liabilities rose 8.24% to $46.1 million in Q2 2025 from the same period last year, while for May 2025 it was $46.1 million, marking a year-over-year increase of 8.24%. This contributed to the annual value of $46.1 million for FY2025, which is 8.24% up from last year.
  • Lifecore Biomedical's Preferred Stock Liabilities amounted to $46.1 million in Q2 2025, which was up 1.99% from $45.2 million recorded in Q1 2025.
  • Over the past 5 years, Lifecore Biomedical's Preferred Stock Liabilities peaked at $46.1 million during Q2 2025, and registered a low of $38.5 million during Q1 2023.
  • Over the past 3 years, Lifecore Biomedical's median Preferred Stock Liabilities value was $42.2 million (recorded in 2024), while the average stood at $42.2 million.
  • Data for Lifecore Biomedical's Preferred Stock Liabilities shows a peak YoY climbed of 8.34% (in 2024) over the last 5 years.
  • Over the past 3 years, Lifecore Biomedical's Preferred Stock Liabilities (Quarterly) stood at $40.9 million in 2023, then rose by 8.28% to $44.3 million in 2024, then grew by 8.24% to $46.1 million in 2025.
  • Its last three reported values are $46.1 million in Q2 2025, $45.2 million for Q1 2025, and $44.3 million during Q4 2024.